Christy Belden is the Director of Digital Marketing at Norton Healthcare — a five-hospital, 1,000-provider regional healthcare network in Louisville, Kentucky. She has worked extensively in all aspects of digital marketing including search, advertising, social media, email, and mobile. Christy has worked at both an agency and on the media side of digital marketing. She speaks, teaches and writes regularly on the subjects of digital marketing. Follow Christy at @christy_belden.
Senior Director, Digital Innovation
Ryan Billings – Senior Director, Digital Innovation
Associate Professor, Director, Law and Health Policy Programme, Director, Law and Life Sciences Programme
UNIVERSITÉ DE SHERBROOKE
Mélanie Bourassa Forcier – Associate Professor, Director, Law and Health Policy Programme, Director, Law and Life Sciences Programme
UNIVERSITÉ DE SHERBROOKE
Dr. Mélanie Bourassa Forcier is the Director of the Health Law and Policy and of the Law and Life Sciences Programs at the University of Sherbrooke, Canada. She holds a Ph.D. in Law from McGill, an M.Sc. in International Health Policy from the London School of Economics and Political Science and an LL.L. summa cum laude from the University of Ottawa. Dr. Bourassa Forcier is a member of the Quebec’s Bar School since 1999. She sometimes acts as a consultant for the Montreal law firm, Fasken.
Dr. Bourassa Forcier has a particular knowledge of the legal framework governing drugs from their inception in the lab to their consumption. Her expertise also covers regulations governing risk-sharing agreements, optimal utilization programs, intellectual property, technology transfers, public and private drug and healthcare coverage.
Dr. Bourassa Forcier is actively involved in the health and life sciences sector in the province of Quebec. She is the author of several books and scientific articles related to health care policy and regulations.
Professor of Computer Science and Engineering
UNIVERSITY OF NOTRE DAME
Nitesh Chawla – Professor of Computer Science and Engineering
UNIVERSITY OF NOTRE DAME
Nitesh Chawla is the Frank M. Freimann Professor of Computer Science and Engineering, and director of the research center on network and data sciences (iCeNSA) at the University of Notre Dame. He is an innovator and entrepreneur in machine learning, data science, and network science with several transformative applications. He is the recipient of several awards and honors including the Outstanding Dissertation Award, Outstanding Teaching Award, IEEE CIS Outstanding Early Career Award, the IBM Watson Faculty Award, the IBM Big Data and Analytics Faculty Award, the National Academy of Engineering New Faculty Fellowship, and 1st Source Technology Commercialization Award. His papers have received several outstanding paper nominations at top venues and also featured on journal cover pages. In recognition of the societal impact of his research, he was recognized with the Rodney Ganey Award and Michiana 40 Under 40. He is the founder of Aunalytics, a data science software and solutions company.
Associate Director, Translational Medicine and Emerging Innovations
Leslie Cousens – Associate Director, Translational Medicine and Emerging Innovations
Leslie earned her Ph.D. in biology and medicine, with a focus on immunology, from Brown University in 1999. Her academic research experience in cellular and molecular immunology includes basic science in small animal models through translational science in cellular immunotherapy. Prior to AstraZeneca, she was leading the research and development efforts for a small biotech company in Providence, Rhode Island. Leslie joined AstraZeneca’s Emerging Innovations Unit in January 2015, where they take an entrepreneurial approach to deliver new medicines through drug repositioning by leveraging external science via the pioneering “open innovation” platform, by incubating novel technologies and by project partnering.
Senior Vice President of Product Marketing
SAAMA TECHNOLOGIES INC.
Karim Damji – Senior Vice President of Product Marketing
SAAMA TECHNOLOGIES INC.
Karim Damji is responsible for product management, marketing, and solution development at Saama Technologies.
Karim joined Saama from Plantronics, where he led software strategy and product management, focusing on driving developer platforms, strategic partner integrations and contextually enabled UC solutions. Prior to joining Plantronics, Karim served in leadership positions spanning business development, product management, sales and network engineering at Cisco, Vocera Communications, MobileIron, and DiVitas. Karim spent 7 years at Cisco building global VoIP and WAN networks, eventually transitioning to product architecture positions. At Vocera Communications and DiVitas, Karim was the founding head of products responsible for driving product concept to market-leading solutions.
Karim has served as a founder and strategic advisor to early-stage startups and is currently involved in mission-driven startups and IoT open-source communities. Karim studied computational and applied mathematics at San Jose State University.
Senior Director Innovation Programs and External Networks
Dany DeGrave – Senior Director Innovation Programs and External Networks
Dany DeGrave currently leads the implementation of various cognitive and other innovative technologies in departments like R&D and Regulatory Intelligence. He also explores and evangelizes blockchain applications in the healthcare space.
Dany is an engineer trained in biology and has over 20 years of industry experience at leading global vaccine companies GSK and Sanofi Pasteur. In various positions, he contributed to the research, product and clinical development, manufacturing and regulatory submission of both companies’ line of vaccines. Next to vaccine and automation projects he developed and lead forward-looking change initiatives like “Project M: An Experiment in New Ways of Working, Inspiring Engagement, and Unleashing Talents” for which the team received multiple international awards.
Vice President, Clinical Innovation and Digital Platforms
Rob DiCicco – Vice President, Clinical Innovation and Digital Platforms
Rob DiCicco is currently the Vice President of Clinical Innovation and Digital Platforms at GlaxoSmithKline. He is also the Work Stream Leader for the Common Protocol Template Project sponsored by TransCelerate BioPharma. Rob has more than 25 years of experience in clinical development in a variety of leadership positions in CRO, mid-sized and large pharmaceutical companies. He received his Doctorate of Pharmacy degree from the University of the Sciences of Philadelphia.
Dr. Fackler’s clinical work is pediatric critical care and anesthesiology at Hopkins. Before taking his current role at Hopkins in 1996, he was on the faculty of the Harvard Medical School where he assisted in the founding of the Children’s Hospital Informatics Program. He worked for the Cerner Corporation from 2002 to 2006 and was responsible for the development and deployment of their critical care solution suite. His academic interests are the harnessing of the data generated by, and about, critically ill children for use in identifying and reducing the clinician driven variability in the care of complex conditions (such as sepsis). He founded a startup, Rubicon Health, to make the variability in healthcare delivery patient-centric and not clinician-idiosyncratic.
Senior R&D Engineer, Depuy-Synthes Joint Reconstruction
JOHNSON & JOHNSON
Ken Fernandez Prada – Senior R&D Engineer, Depuy-Synthes Joint Reconstruction
JOHNSON & JOHNSON
Professor, Departments of Medicine and Cell and Molecular Medicine
UC SAN DIEGO
Pradipta Ghosh – Professor, Departments of Medicine and Cell and Molecular Medicine
UC SAN DIEGO
Analytics Executive in Residence
UNIVERSITY OF DENVER
Evon Holladay is a seasoned professional in architecting enterprise intelligence solutions and running analytics operations. She has built scalable, high-value solutions for healthcare, telecommunications, retail, and manufacturing. She is passionate about working with a broad range of stakeholders to develop a strategy and then operationalize the strategy into solutions that provide measurable value.
As the former Vice President Enterprise Intelligence for Catholic Health Initiatives (CHI), she led CHI’s Population Health Analytics and Data strategy. This included the formation of an industry-leading information management governance structure for CHI’s analytics portfolio, enterprise data warehouse, data governance and enterprise information architecture.
Currently, she is using her research skills to help provide new insight into the health-healthcare-health insurance conundrum. She is collaborating with a broad range of viewpoints — in the US and internationally — ranging from health economists, healthcare providers, health insurance, and alternative medicine. Her research is focused on the impact of healthcare spending on personal income and the changes in the health of the US population.
She also is an analytics advisory board member for DU’s Business Information and Analytics department. She regularly presents her work nationally and internationally. At DU she guest-lectures and works with her business peers to provide timely capstone project opportunities.
Dr. Jiang as Chief Strategy Officer of Xtalpi Inc. is responsible for company’s strategy development including identification of growth opportunities, strategic planning, and execution. He joined Xtalpi in 2015 bringing over fifteen years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme and then Sanofi-Genzyme. His early tenure at Genzyme was in disease biology research focusing on oncology and genetic diseases. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Jiang was appointed as liaison and director of Asia R&D Strategy of the Sanofi-Genzyme R&D Center and in that capacity was responsible for the development of Genzyme Asia/China R&D strategy and led cross-functional R&D external collaborations and projects in Asia. He was also a key member of the Translational Medicine team and focused on strategic implementation of pharmacogenomics and biomarker in early clinical development.
Before joining in industry, Alan received his medical degree and a doctorate in molecular biology followed by post-doctoral research in hematology and oncology at Brigham & Women’s Hospital, Harvard Medical School.
Professor Stan Kachnowski, Ph.D., MPA, RSM, an Oxford-trained researcher, has taught over 5,000 students from Columbia University, IIT-Delhi, and Quinnipiac College. His teaching and research over the past 27 years include educating graduate level and executive students on 4 continents and conducting extensive studies on the efficacy and diffusion of digital health, including electronic machine learning, blockchain, data capture, ePRO, wearables, and predictive algorithms.
Professor Kachnowski has authored over 200 peer-reviewed papers and presentations for national and international journals and societies in digital health development, management, and diffusion. He was selected as a Fellow to CHIME in 1998. In 2003 he received a letter of commendation for teaching excellence from the Dean of the School of Public Health at Columbia University. Professor Kachnowski was named a Fellow to England’s Royal Society of Medicine for his research demonstrating the outcomes effectiveness of using the Palm Pilot in managing hemophilia patients in 2005. Professor Kachnowski has received grant funding from a wide-ranging group of sponsors, including over a dozen nations, AARP, WHO, USAID, Gates and Dell Foundations, and most of the top 20 global life science companies. Over the past 25 years, he has also served as interim CTO for life science organizations, including Eyetech and Oncology.com. He currently serves on the Board of Directors for Oursmedicina, The Hudson Center for Health Equity, and Aptus Health.
Professor Kachnowski holds Bachelors and Master’s Degrees from the University of Vermont, and a Doctorate from the University of Oxford.
Wayne C. Koff, Ph.D., is founding President & CEO of the Human Vaccines Project, a public-private partnership with the goal of decoding the human immune system to accelerate development of vaccines and immunotherapies for major infectious diseases and cancers. Prior to joining the Project, he served as CSO & Senior VP, R&D, at the International AIDS Vaccine Initiative; there, Dr. Koff’s accomplishments included: Developing multiple HIV vaccines through clinical trials; Establishing state-of-the art laboratories in the US, Europe, India and Africa; Conducting the first HIV vaccine trials in India, Kenya, and Rwanda; Establishing the Neutralizing Antibody Consortium identifying new, broad and potent neutralizing antibodies against HIV leading to the discovery of novel targets for vaccine design; and, Established a clinical research network in Africa which conducted seminal studies on HIV pathogenesis, incidence, and acute infection. Dr. Koff has published more than 100 scientific papers and edited eight books on vaccine development.
, Pharm.D., M.S., Esq.
Vice President, Regulatory Strategy and Policy
SYNCHROGENIX, A CERTARA COMPANY
Darshan Kulkarni – Vice President, Regulatory Strategy and Policy
SYNCHROGENIX, A CERTARA COMPANY
Dr. Kulkarni is Vice President of Regulatory Strategy and Policy at Synchrogenix. He is responsible to help guide policy development and engagement strategies using various methodologies including, but not limited to artificial intelligence, the blockchain, big data etc.
He has multiple patent filings to his name and owns various forms of intellectual property rights including copyrights, trademarks etc.
He is routinely called on because of his over 15 years of experiences working on the legal and regulatory requirements associated the Food Drugs and Cosmetics Act, state and federal versions of the Anti-Kickback Law, Civil Monetary Penalties Act, False Claims Act, Sunshine Act, HIPAA, 21st Century Cures Act etc.
He regularly works with issues relating to a variety of local, state, federal and international agencies including, but not limited to the United States (US) Food and Drug Administration (FDA), United States Department of Agriculture (USDA), Drug Enforcement Administration (DEA), United States Department of Justice (DOJ) and International Conference on Harmonization (ICH).
Dr. Kulkarni has over 20 years of experience as a clinician having worked in numerous pharmacy settings including retail, hospital, long-term care, hospice, and others. He lectures and teaches extensively globally on various issues relating to the life sciences including Johns Hopkins University, Thomas Jefferson University Medical School, Temple Law School and Temple pharmacy school, Drexel University, University of Florida, University of Southern California etc. He is currently Visiting Professor at the University of the Sciences, in their Biomedical Writing Program, where he has taught for over 10 years and received an Outstanding Adjunct Teaching Award. He regularly gives keynote talks at various events including DIA, and AALNC and others.
Dr. Kulkarni serves on various Editorial and Advisory Boards including for FDANews and Applied Clinical Trials. He serves in the American Bar Association where he participates and is actively involved in the Healthcare Fraud Section, Life Sciences Section, and Distance Learning Section. He is a former board member of the National Bar Association’s Health Law Section.
Most recently, Dr. Kulkarni has written several articles, and chapters for textbooks including the chapter on Medical Devices, Drug Advertising, Drug Compounding, and pharmaceutical reimbursement for the Second, Third, Fourth and upcoming Fifth Edition of Pharmaceutical and Medical Device Law - Regulation of Research, Development, and Marketing, Second Edition – the American Bar Association’s flagship textbook for pharmaceutical and medical device law.
Craig Lipset is Director of Health Technologies at Pfizer, working from the company’s New York corporate headquarters.
At Pfizer, Craig is responsible for technology-based initiatives spanning clinical and commercial. Serving as Platform Leader for patient adherence technologies, Craig is working at a transactional as well as strategic level in the appropriate application of technologies to monitor and influence adherence.
Prior to Pfizer, Craig served as Associate Vice President of Program Management at Adnexus Therapeutics (acquired by Bristol-Myers Squibb), where he was responsible for Toxicology, Clinical and Regulatory. He served as President of Critical Path Imaging, a consulting firm improving the use of medical imaging in drug development. Craig was a founding employee of Perceptive Informatics, a clinical technology services and software company (later operating as a subsidiary of Parexel International), where he was Head of Operations and Business Development for the company’s core lab business.
He serves on the editorial board of the Drug Information Journal and as an advisor to a patient research and advocacy organization.
Martin (Marty) Lupinetti brings 25+ years of healthcare-public sector experience providing executive leadership, strategic planning, governance, policy and technology implementation and deployment oversight to a variety of healthcare and public sector entities in the region. His engagement with the HSX effort began in the fall of 2011 in a consulting role through the North Highland Company, in which Martin led the development of the initial business plan, governance, and financial sustainability model for HealthShare Exchange.
Marty and his accomplished staff at HSX now work with more than 50 member/participant hospitals, insurers, ambulatory practices, and other healthcare facilities to establish health information exchange capabilities that include Direct, Enhanced Direct, ENS, and Query services. These technologies have already begun to make patient clinical information available electronically and securely to the area’s insurers, medical centers, and practice offices to support more-informed patient care at the point of care.
At the North Highland Company, Marty was a Principal and Public Sector Lead, managing efforts in Health IT and the public sector in the region. Prior work history includes Deloitte Consulting, PwC, and CSC, where he focused on large IT management, shared services, project management and software development consulting services and support.
Marty serves as secretary of the board of the Delaware Valley Healthcare Information Management Systems Society (DVHIMSS) and chairs programs/events for DVHIMSS.
Rishi Madhok – Chief Executive Officer and Co-Founder
Rishi Madhok, M.D., is a board-certified emergency medicine physician who focuses on bridging the gap between technology and medicine. Prior to founding BitMED, Rishi partnered with the Harvard Humanitarian Initiative, Rishi was the technical lead expert in the development of portable medical software to analyze the health needs of refugee and third world populations.
Rishi’s research has led to significant medical innovations and has been presented both nationally and internationally. Rishi was previously Director of Clinical Informatics at the University of Pennsylvania hospital. He has also been a medical advisor to multiple small and medium stage companies, including Warby Parker, Wellzio, and Good Parents Inc.
Rishi obtained his medical degree at Columbia University College of Physicians and Surgeons and completed his emergency medicine residency training at NewYork-Presbyterian Hospital — the University Hospital of Columbia & Cornell. Rishi was among the earliest physicians to become board certified in the emerging field of Clinical Informatics.
Director Center for Supply Chain Innovation
TEXAS CHRISTIAN UNIVERSITY
Dave Malenfant – Director Center for Supply Chain Innovation
McCall McIntyre is an investor at Samsung NEXT Ventures, an early-stage fund dedicated to investments in software and services on behalf of Samsung Electronics, where she focuses on opportunities in the HealthTech, big data, AI/ML and IDaaS spaces. Prior to joining Samsung NEXT, McCall developed expertise in implementing and scaling machine learning dependent product offerings at Simulmedia, an NYC AdTech company focused on optimizing the ROI of media spend on linear TV for some of the largest advertisers in the US.
Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William Paiva – Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William D. Paiva, Ph.D., is Executive Director of Oklahoma State University’s Center for Health Systems Innovation (CHSI). The Center is focused on transforming rural and Native America health through the implementation of innovative care delivery and IT solutions. Within CHSI, the Institute for Predictive Medicine is applying advanced analytics to the largest health care database which includes clinical information for over 63 million patients covering 16 years.
Prior to joining Oklahoma State University, Dr. Paiva was a partner, joined Sevin Rosen Funds, a fund with over $2 billion under management, where he brought more than 20 years of venture-capital, biomedical-industry and management-consulting experience to the firm. William specialized in identifying early-stage venture opportunities at the intersection of traditional technology sectors and healthcare. He also used his healthcare expertise and network to assist Sevin Rosen portfolio companies developing applications and services for the healthcare market. Prior to Sevin Rosen, William was a partner at Chisholm Private Capital Partners, where he managed a $100 million fund focused on healthcare and IT. He also worked as a manager at the Oklahoma Life Science Fund, managing $15 million and making investments in diagnostics, services and therapeutics firms.
Before that, William served as a management consultant for the Life Sciences Industry Group at Pittiglio Rabin Todd & McGrath, later acquired by PriceWaterhouseCoopers, where he consulted with the top five pharmaceutical companies on product-development and technology-management projects. William also served as an investment banking associate at JP Morgan in New York, providing strategic and investment banking advisory services to Fortune 100 healthcare companies.
William holds a Ph.D. in molecular biology from the University of Oklahoma; an MBA from Dartmouth College’s Amos Tuck School of Business; a master’s degree in microbiology and immunology from the University of Oklahoma Health Science Center; and a B.S. in microbiology from the University of Oklahoma.
Director, Communities and Initiatives Development, Emerging Technology
IEEE STANDARDS ASSOCIATION
Maria Palombini – Director, Communities and Initiatives Development, Emerging Technology
IEEE STANDARDS ASSOCIATION
Maria is the creator, leader and advocate for the Pharma Blockchain Initiative, which seeks to bring awareness and balanced learning to the pharmaceutical community and its key stakeholders on the viable applications of blockchain within the pharmaceutical framework. The goal of the initiative is the advanced adoption of blockchain in combination with emerging technologies (ie. AI, IoT, etc) where it will lead to enhanced patient safety and care, and optimize and innovate the drug development life cycle.
In 2017, Maria joined IEEE-SA with a directive to build communities and advance initiatives to develop standards for enterprise adoption of emerging technologies. Her work includes building communities of technologists, industry executives, academic researchers and industry stakeholders to educate on the benefits and challenges of viable applications of emerging technologies while building consensus on recommendations for frameworks on technical standards and recommended guidelines for protocol and policies to enhance the outcomes of technology implementation. Her primary areas of focus include the pharma, health, supply chain, energy, and agriculture sectors. In parallel to her work in blockchain standards, she is the project lead for IEEE-SA’s newest initiative, Digital Inclusion through Trust and Agency, a critical program focused on bringing the outstanding 50% of the world’s population online while working with technologists, advocacy groups and policy leaders on developing trusted frameworks that will protect the digital persona, the right to be forgotten, and restoring dignity to digital transactions for ALL members of the global community.
In 2015, Maria left Euromoney Plc, one of the world’s leading information and event producers. She founded DisruptiveRx™, an information company that would produce written and in-person educational programs and bring pragmatic attention to breakthrough innovations that would transform life sciences and healthcare enterprise operations.
Her career started at the prestigious IEEE (Institute for Electronic and Electrical Engineers) and moved onto highly respected media companies including Penton Media, Advanstar Communications, IIR, Reed Business Information and Nielsen Business Media. She successfully led the global branding, marketing, and public relations campaign for the world’s largest mining investment networking platform, Mining Indaba™, in Cape Town, South Africa.
Maria currently holds an MBA from the Rutgers Graduate School of Business and a BA and BS from Rutgers College at Rutgers University, the State University of New Jersey. She is an accomplished leader and public speaker having presented at various industry events. You can follow her on twitter @DisruptiveRx or on LinkedIn.com/in/mpalombini.
Aris Persidis is President and co-founder of Biovista. He is responsible for outreach and business development and has helped design the specifications and tracking of the Project Prodigy AI. Aris authored the Industry Trends column for Nature Biotechnology, was a judge for the 2011 Top-10 Innovations of The Scientist and served as the inaugural co-Editor-in-Chief of Drug Rescue, Repurposing and Repositioning. He was SVP, Business Development for Upstate Bio (acquired by Serologicals), Managing Director of Rheogene (acquired by Intrexon), and participated in the cofounding of Cellzome (acquired by GSK), and Anadys (acquired by Roche). Aris was also adjunct assistant professor at Wharton and holds a Ph.D. in biochemistry from Cambridge.
Head, AI Center for Excellence
Josh Raysman – Head, AI Center for Excellence
, M.D., Ph.D.
Professor and Chair, Department of Radiology
UNIVERSITY OF OTTAWA FACULTY OF MEDICINE
Frank Rybicki – Professor and Chair, Department of Radiology
UNIVERSITY OF OTTAWA FACULTY OF MEDICINE
Frank J. Rybicki, MD, Ph.D., is Professor and Chair of Radiology at the University of Ottawa and The Ottawa Hospital. Dr. Rybicki is the Medical Director for Imagia, a leader in artificial intelligence. In 2007, Dr. Rybicki introduced wide-area detector CT to radiology. He also made the initial observation that contrast hemodynamics are related to blood flow. Both of these technologies are now globally used for patient care and research. Dr. Rybicki pioneered medical 3D printing in healthcare; he is the Editor-in-Chief of 3D Printing in Medicine and in 2014 he founded and was the first Chairperson of the Radiological Society of North America Special Interest Group on 3D printing.
Malaikannan Sankarasubbu is the VP of AI Research in Saama Technologies. He is currently working on optimizing and accelerating clinical trials using Artificial Intelligence. He specializes in deriving insights with unstructured data like text and images. He previously was Founder and CTO for Datalog.ai creators of MyPolly, a chatbot building platform with its own Natural Language Understanding Engine where he built a community of 1,200 active developers, aka chatbot builders, around MyPolly. Malaikannan was part of the Enterprise Architecture team in Optum and Cognizant Technology Solutions. He understands Healthcare and is passionate about advancing more applications of Deep Learning in Healthcare and Life Sciences. Malaikannan loves building community; he along with few others built a community around Keras and he also created an active forum Indian Deep Learning Initiative which has over 4,500 members. Malaikannan actively shares his knowledge in Meetups and conferences and loves to blog about Artificial Intelligence at malaikannan.io.
, R.Ph., MBA, LSSMB
Director, Specialty Clinical Innovation and Program Development
Christine Sawicki – Director, Specialty Clinical Innovation and Program Development
Christine leads innovation for CVS Health’s Specialty division. Her team identifies and introduces solutions that improve patient experience, enhance clinical care, and provide cost-effective solutions to deliver the highest level of clinical care.
Ms. Sawicki has more than 25 years’ experience with CVS Health. She has also led pharmacy design and technology and pharmaceutical water system innovation and was a practicing pharmacist in the health plan, retail, hospital, and long-term care settings. Christine is a three-time CVS Health Breakthrough Award recipient for innovations and business solutions.
Ms. Sawicki received holds a B.A. in Chemistry from Assumption College where she is also adjunct faculty for MBA and Health Advocacy programs, Pharmacy Degree from MCPHSU, MBA from Anna Maria College, Lean Six Sigma Master Black Belt from Villanova University, and Pharmacoeconomic Certification from the University of South Carolina.
Associate Vice President Technology Development
NEW JERSEY INSTITUTE OF TECHNOLOGY
Judith Sheft – Associate Vice President Technology Development
NEW JERSEY INSTITUTE OF TECHNOLOGY
Judith A. Sheft is the Associate Vice President Technology and Enterprise Development at New Jersey Institute of Technology (NJIT). She manages the university’s technology commercialization efforts through programs and policies focusing on patent creation, intellectual property valuation, strategic use and protection of IP assets. She works with faculty and students to create startup companies. She is involved with regional economic development having responsibilities for the management of NJTI’s high technology/life sciences business accelerator/incubator, the HealthIT Connections entrepreneurial cluster development program and the Procurement Technical Assistance Center. She is on the Board of Advisors to the NJIT Murray Women’s Center and helps mentor students and faculty. She is a member of the NJ – Israel Commission and serves on the Board of the New Jersey Entrepreneurs Network, Greater Newark Enterprise Corporation, Women’s Center for Entrepreneurship Corporation and Einstein’s Alley, working to assist early-stage tech and life sciences entrepreneurs.
Justin Smith, Ph.D. leads the development of advanced analytics as Enterprise Director of Data and Analytics for Sanford Health, an organization with over 29,000 employees, 43 hospitals, and 250 clinics across nine states and three countries.
Dr. Smith leads teams, in collaboration with executive leaders, to build machine learning models that enable Sanford to better understand business drivers. Dr. Smith employs a unique skill set of strong analytical skills and thought-leadership as Sanford Health transitions from the world of advanced analytics to artificial intelligence.
Dr. Smith has published numerous articles in peer-reviewed international journals. He holds a Ph.D. in the field of Neuroscience and an M.S. and B.S. in Research Psychology.
Kelly Stanton – Data Scientist
Chief Technology Officer
Saheel Sutaria – Chief Technology Officer
Product Strategy and Management, Personalized Healthcare and Digital Health
Jennifer Turcotte – Product Strategy and Management, Personalized Healthcare and Digital Health
Jennifer is an Associate Director, Personalized Healthcare and Digital Health Strategy in Pharma Informatics at Genentech. Jennifer has more than 20 years of experience in product strategy, management, and marketing in biotechnology and software companies. Prior to Genentech, she held leadership roles in marketing at GuideSpark, Veeva, Complete Genomics, SAP, Siperian/Informatica and Ariba. Jennifer holds a Bachelor of Engineering – Mechanical from Carleton University in Ottawa, Canada
Richard Wendell is a technology executive with over two decades of experience leading data science teams to disrupt legacy approaches to research, development, and engineering. Currently, Mr. Wendell is the Founder and CEO of tellic LLC, a technology startup that develops artificial intelligence (AI) tools for Pharmaceutical R&D and commercial. Prior to tellic, he served as a Chief Data Officer and in various Executive and Advisory Roles for TE Connectivity, American Express, AT&T, and Intel. Mr. Wendell has served on the Board of Directors for MIT’s International Society for Chief Data Officers and the New York Venture Capital Association. He holds a Master of Science in Advanced Analytics from Carnegie Mellon.
Join Our Faculty!
To inquire about becoming an faculty, contact Emily Sternberg at email@example.com